Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Discovery of a cyclic cell-penetrating peptide with improved endosomal escape and cytosolic delivery efficiency
Its two RLT products Lutathera (lutetium-177 DOTATATE) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and Pluvicto (lutetium-177 PSMA-617) for metastatic castration-resistant prostate cancer represent the most commercially advanced radioligand therapy platform in the world and occupy the Oncology Peptide Therapy segment, which the report forecasts to grow at 11.79% CAGR through 2031
For patients managing chronic conditions, hormonal issues, or complex health goals, physician supervision is clinically meaningful
Eventually, those bad food choices will end up making you bigger and bigger
US$ 29.09
US$ 20.15
US$ 22.05
US$ 21.72
US$ 22.45
US$ 29.21
